Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS AND METHODS: A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank tests and Cox models. RESULTS: In 664 tumors, no mutation was detected, 462 tumors were diagnosed with KRAS-, 39 patients with NRAS- and 74 patients with BRAF-mutation. Mutations in KRAS were associated with inferior progression-free survival (PFS) and overall survival (OS) [multivariate hazard ratio (HR) for PFS: 1.20 (1.02-1.42), P = 0.03; multivariate HR for OS: 1.41 (1.17-1.70), P < 0.001]. BRAF mutation was also associated with inferior PFS [multivariate HR: 2.19 (1.59-3.02), P < 0.001] and OS [multivariate HR: 2.99 (2.10-4.25), P < 0.001]. Among specific KRAS mutation variants, the KRAS G12C-variant (n = 28) correlated with inferior OS compared with unmutated tumors [multivariate HR 2.26 (1.25-4.1), P = 0.001]. A similar trend for OS was seen in the KRAS G13D-variant [n = 71, multivariate HR 1.46 (0.96-2.22), P = 0.10]. More frequent KRAS exon 2 variants like G12D [n = 152, multivariate HR 1.17 (0.86-1.6), P = 0.81] and G12V [n = 92, multivariate HR 1.27 (0.87-1.86), P = 0.57] did not have significant impact on OS. CONCLUSION: Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Approximately 45% of patients diagnosed with mCRC have KRAS mutations, and the presence of mutations is important both in terms of prognosis [9,10].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [9]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the KRAS p.G12C mutation is associated with poorer prognosis in terms of progression-free survival (PFS) and overall survival (OS) compared to other KRAS mutations as well as KRAS wild-type tumors.4-7”
From Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A pooled analysis by the Arbeitsgemeinschaft Internistische Onkologie [AIO] study group revealed that KRAS G12C mutation was significantly associated with lower OS compared with tumors with no KRAS mutations [16]”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with other KRASm, including KRAS G12A/D/S/V and KRAS G13D, had OS times ranging from 17.6 to 25.2 months.51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
In the citing paper
“A post hoc analysis of pooled clinical data from 1239 patients from 5 randomized trials, in which patients with mCRC were treated with chemotherapy with or without bevacizumab as first-line treatment (67%), reported that patients harboring KRAS G12C had the shortest median OS (16.8 [95% CI: 15.6, 18.0] months).51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 3×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 2×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · cited 1×
“patients andmethods studies This analysis is based on individual patient data from five first-line trials in mCRC: FIRE-1 [14, 15], FIRE-3 (only bevacizumab-arm) [2, 16, 17], AIO KRK 0604 [18], AIO KRK 0207 [19] and RO91 [20].”
MethodSelf-citationCremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 3×
“well with recent reports of first-line treatment in mCRC [5, 24].”
BackgroundResultVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationBokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Research works printed but not linked: 1
- 19. Stintzing S, Jung A, Rossius L, Modest DP et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. In ESMO/ECCO, 2013; Abstract E17-7073.
Cited by
Items 101–200 of 351
Aldiab, A., Al Khayal, K. A., Al Obaid, O. A., Alsheikh, A., Alsaleh, K., Shahid, M., & Alkharji, H. (2017) · Oncology · doi:10.1159/000450857 · Cited by 19
Ciracì, P., Germani, M. M., Pietrantonio, F., Manca, P., Lonardi, S., Busico, A., Bergamo, F., Burgio, V., Mannavola, F., Donato, S. D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.002 · Cited by 31
Contemporary Surgical Management of Colorectal Liver Metastases
Chandra, P., & Sacks, G. D. (2024) · Cancers · doi:10.3390/cancers16050941 · Cited by 24
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives
Personeni, N., Smiroldo, V., Giunta, E. F., Prete, M. G., Rimassa, L., Bregni, G., & Sclafani, F. (2021) · Cancers · doi:10.3390/cancers13184506 · Cited by 20
Hu, Y., Tao, S.-Y., Deng, J.-M., Hou, Z., Liang, J., Huang, Q.-G., Li, L.-H., Li, H., Chen, Y., Hua, Y., et al. (2018) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2018.19.11.3001 · Cited by 22
Fedyanin, M. Y., Ehlsnukaeva, К. M., Демидова, И. А., Stroyakovskiy, D., Shelygin, Y. A., Цуканов, А. С., Панина, М. В., Шубин, В. П., Moiseenko, F. V., Karpenko, E. Y., et al. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-4s-52-63 · Cited by 37
Afrăsânie, V.-A., Marinca, M. V., Gafton, B., Alexa‐Stratulat, T., Rusu, A., Froicu, E.-M., Sur, D. G., Lungulescu, C. V., Popovici, L., Lefter, A.-V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612679 · Cited by 20
Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR
López, S. O., Lévano-Linares, D. C., Auz, C. L., Vega-Clemente, L., Sánchez, E. L., Villagrasa, A., Ruíz-Tóvar, J., García‐Arranz, M., & García‐Olmo, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i39.7087 · Cited by 22
Yuan, Y., Liu, Y., Wu, Y., Zhang, J., Shen, C., Zhang, F., Wu, C., & Hu, W. (2021) · The International Journal of Biological Markers · doi:10.1177/17246008211017152 · Cited by 23
Uutela, A., Österlund, E., Halonen, P., Kallio, R. S., Ålgars, A., Salminen, T., Lamminmäki, A., Soveri, L., Ristamäki, R., Lehtomäki, K., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01858-8 · Cited by 20
Yoshino, T., Cutsem, E. V., Li, J., Shen, L., Kim, T. W., Sriuranpong, V., Xuereb, L., Aubel, P., Fougeray, R., Cattan, V., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100511 · Cited by 19
Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
Zhong, L., Wang, R., Wang, Y., Peng, S., Ma, Y., Ding, S., Yang, H., Chen, S., Luo, X., & Wang, W. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.001 · Cited by 21
Avallone, A., Piccirillo, M. C., Gennaro, E. D., Romano, C., Calabrese, F., Roca, M. S., Tatangelo, F., Granata, V., Cassata, A., Cavalcanti, E., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920929589 · Cited by 19
NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study
Wu, K., Li, S.-H., Liao, J.-B., Chiou, C.-C., Wu, C., & Chen, C. (2021) · Biology · doi:10.3390/biology10050396 · Cited by 17
Tabernero, J., Taieb, J., Fakih, M., Prager, G. W., Van Cutsem, E., Ciardiello, F., Mayer, R. J., Amellal, N., Skanji, D., Calleja, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102945 · Cited by 18
Fernandes, G. D. S., Braghiroli, M. I., Artioli, M., Paterlini, A. C. C. R., Teixeira, M. C., Gumz, B. P., Girardi, D. M., Braghiroli, O. F. M., Costa, F. P., & Hoff, P. M. (2017) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-017-0001-3 · Cited by 17
Specific Mutations in APC, with Prognostic Implications in Metastatic Colorectal Cancer
Peng, H., Ying, B., Zang, J., Lu, H., Zhao, X., Yang, P., Wang, X., Li, J., Gong, Z., Zhang, D., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.415 · Cited by 18
KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells
Patankar, M., Eskelinen, S. M., Tuomisto, A., M�kinen, M. J., & Karttunen, T. J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10693 · Cited by 20
Precision medicine for adjuvant chemotherapy of resected colorectal cancer
Miyamoto, Y., Hiyoshi, Y., Sawayama, H., Tokunaga, R., & Baba, H. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12397 · Cited by 14
Diagnostic and therapeutic biomarkers in colorectal cancer: a review.
de Assis, J. V., Coutinho, L. A., Oyeyemi, I. T., Oyeyemi, O. T., & Grenfell, R. F. Q. (2022) · PubMed Central · Cited by 47
Yuan, Y., Deng, Y., Jin, Y., Guo, Z., Pan, Y., Wang, C., Wang, Z., Hu, Y., Hua, D., Meng, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02315-7 · Cited by 22
Gau, L., Ribeiro, M., Pereira, B., Poirot, K., Dupré, A., Pezet, D., & Gagnière, J. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.05.039 · Cited by 15
Simkens, G. A. A. M., Wintjens, A. G. W. E., Rovers, K. P. B., Nienhuijs, S. W., & de Hingh, I. H. J. T. (2021) · Cancer Management and Research · doi:10.2147/cmar.s277912 · Cited by 20
Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 17
Fang, X., Zhong, C., Weng, S., Hu, H., Wang, J., Xiao, Q., Wang, J., Sun, L., Xu, D., Liao, X., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11139-z · Cited by 16
Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer
Cheng, H., Lin, J.-K., Chen, W.-S., Jiang, J., Yang, S.-H., & Chang, S. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3095-6 · Cited by 16
Redefining Colorectal Cancer by Tumor Biology
Salem, M. E., Puccini, A., & Tie, J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279867 · Cited by 14
Biomarkers in the development of individualized treatment regimens for colorectal cancer
Crutcher, M. M., & Waldman, S. A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1062423 · Cited by 15
KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer
Aljehani, M. A., Bien, J. Y., Lee, J. S. H., Fisher, G. A., & Lin, A. Y. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.45801 · Cited by 19
Sebuyoya, R., Sevcikova, S., Yusuf, B., & Bartošík, M. (2025) · Talanta · doi:10.1016/j.talanta.2025.127709 · Cited by 16
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 18
Zwart, K., van der Baan, F. H., Cohen, R., Aparicio, T., de la Fouchardière, C., Lecomte, T., Punt, C. J. A., Sefrioui, D., Verheijden, R. J., Vink, G. R., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6223 · Cited by 14
Miyamoto, Y., Akiyama, T., Kato, R., Sawayama, H., Ogawa, K., Yoshida, N., & Baba, H. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002392 · Cited by 15
Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
Gökmen, İ., Taştekin, E., Demir, N., Özcan, E., Akgül, F., Hacıoğlu, M. B., Erdoğan, B., Topaloğlu, S., & Çiçin, İ. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100491 · Cited by 14
Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases
Tonello, M., Baratti, D., Sammartino, P., Giorgio, A. D., Robella, M., Sassaroli, C., Framarini, M., Valle, M., Macrì, A., Graziosi, L., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102976 · Cited by 13
Orlandi, E., Giuffrida, M., Trubini, S., Luzietti, E., Ambroggi, M., Anselmi, E., Capelli, P., & Romboli, A. (2024) · Diagnostics · doi:10.3390/diagnostics14101001 · Cited by 17
Sun, Z., Shi, M., Xia, J., Li, X., Chen, N., Wang, H., Gao, Z., Jia, J., Peng, Y., Ji, D., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010460 · Cited by 16
Liu, Z., Li, Y., Wang, S., Wang, Y., Sui, M., Liu, J., Chen, P., Wang, J., Zhang, Y., Dang, C., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03338-2 · Cited by 19
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
Rosati, G., Aprile, G., Colombo, A., Cordio, S. S., Giampaglia, M., Cappetta, A., Porretto, C. M., Stefano, A. D., Bilancia, D., & Avallone, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051035 · Cited by 15
Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S. (2024) · Cancers · doi:10.3390/cancers16183136 · Cited by 12
“In contrast, cases with KRAS mutation tend to have a worse prognosis, consistent with previous reports [32].”
ResultŽilinskas, J., Stukas, D., Jasukaitienė, A., Šapauskienė, J., Banienė, R., Trumbeckaitė, S., Švagždys, S., Cicciù, M., Dambrauskas, Ž., Gulbinas, A., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04777-0 · Cited by 15
Ren, J., Xu, G., Liu, H., He, N., Zhao, Z., Wang, M., Gu, P., Zhu, C., Deng, Y., Wu, D., et al. (2023) · Biosensors · doi:10.3390/bios13080778 · Cited by 14
Zwart, K., van Nassau, S. C. M. W., van der Baan, F. H., Koopman, M., Snæbjörnsson, P., van Gestel, A. J., Vink, G. R., & Roodhart, J. M. L. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02711-w · Cited by 13
Jazieh, K., Tsai, J., Solomon, S. R., Zhu, M., Sinicrope, F. A., Pedersen, K. S., Fernández-Zapico, M. E., & Xie, H. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2948 · Cited by 15
Lawler, T., Parlato, L., & Andersen, S. W. (2023) · Cancer Causes & Control · doi:10.1007/s10552-023-01783-y · Cited by 21
Alfonso, P. G., Benavides, M., Falcó, E., Martín, A. J. M., Gómez, A., Sastre, J., Rivera, F., Montagut, C. O., Salgado, M., López-Ladrón, A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0316 · Cited by 12
Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS
Margalit, O., Shacham‐Shmueli, E., Lawrence, Y. R., Yang, Y., Reiss, K. A., Golan, T., Mamtani, R., Halpern, N., Aderka, D., Giantonio, B. J., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.06.001 · Cited by 14
Imaging predictors of BRAF mutation in colorectal cancer
Eurboonyanun, K., Lahoud, R. M., Kordbacheh, H., Pourvaziri, A., Promsorn, J., Chadbunchachai, P., O’Shea, A., Atre, I. D., & Harisinghani, M. G. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02484-9 · Cited by 13
Jiang, Y., Liu, Y., Huang, H., Zhao, T., Zhao, Z., & Gao, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03926-9 · Cited by 12
KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania
Brînzan, C., Aşchie, M., Cozaru, G. C., Deacu, M., Dumitru, E., Burlacu, I., & Mitroi, A. F. (2022) · Medicine · doi:10.1097/md.0000000000030979 · Cited by 12
Ren, L., Zhu, D., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, R., Ye, Y., Zhang, S., et al. (2023) · Clinical Surgical Oncology · doi:10.1016/j.cson.2023.100013 · Cited by 12
Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer
Michl, M., Taverna, F., Kumbrink, J., Schiergens, T. S., Heinemann, V., Engel, J., Kirchner, T., & Neumann, J. H. L. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02983-6 · Cited by 15
Self-citationTakeda, H., & Sunakawa, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602194 · Cited by 11
Liu, X., Ou, K., Ma, X., Gao, L., Wang, Q., Zhang, H., & Yang, L. (2022) · BMC Cancer · doi:10.1186/s12885-022-09889-3 · Cited by 14
Sayagués, J. M., del Carmen, S., Abad, M., Corchete, L. A., Bengoechea, Ó., Anduaga, M. F., Baldeón, M. J., Cruz, J. J., Alcázar, J. A. S., Angoso, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25300 · Cited by 13
Yildirim, H. C., Gunenc, D., Almuradova, E., Sutcuoglu, O., & Yalcin, S. (2025) · Medicina · doi:10.3390/medicina61030408 · Cited by 10
“KRAS mutations are observed in approximately 45% of patients diagnosed with advanced CRC, whereas these mutations are detected in 15–37% of early-stage cases [46,47].”
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10
“Approximately 45% of patients diagnosed with mCRC have KRAS mutations, and the presence of mutations is important both in terms of prognosis [9,10].”
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 15
Alig, A. H. S., Modest, D. P., Stintzing, S., Heinrich, K., Geißler, M., von Weikersthal, L. F., Decker, T., Vehling‐Kaiser, U., Held, S., Moosmann, N., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103677 · Cited by 11
Self-citationMa, J., Nie, X., Kong, X., Xiao, L., Liu, H., Shi, S., Wu, Y., Li, N., Hu, L., & Li, X. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01439-6 · Cited by 12
Kale, R. R., Samant, C., Nandakumar, K., Pai, K. S. R., & Bhonde, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151688 · Cited by 12
Chen, K., Wang, H., Collins, G. P., Hollands, E. C., Law, I. Y. J., & Toh, J. W. T. (2022) · Current Oncology · doi:10.3390/curroncol29030116 · Cited by 11
Montés, A. F., Alonso, V., Aranda, E., Élez, E., Alfonso, P., Grávalos, C., Maurel, J., Vera, R., Vidal, R., & Aparicio, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03199-1 · Cited by 16
Hlaváč, V., Červenková, L., Šůsová, S., Holý, P., Liška, V., Vyčítal, O., Šorejs, O., Fiala, O., Daum, O., & Souček, P. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00557 · Cited by 10
Hjortborg, M., Edin, S., Böckelman, C., Kaprio, T., Li, X., Gkekas, I., Hagström, J., Strigård, K., Haglund, C., Gunnarsson, U., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-80803-6 · Cited by 12
Zou, J., Shi, X., Wu, Z., Zuo, S., Tang, X., Zhou, H., & Huang, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102235 · Cited by 14
Wang, X.-D., Lin, J.-H., & Hu, M.-H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108164 · Cited by 13
Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI
Volovăț, S. R., Augustin, I. G., Zob, D., Boboc, D., Amurariti, F., Volovat, C. D., Ştefănescu, C., Stolniceanu, C. R., Ciocoiu, M., Dumitras, E. A., et al. (2022) · Cancers · doi:10.3390/cancers14194834 · Cited by 12
KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
Lian, S., Tan, L.-X., Liu, X.-Z., Yang, L., Li, N.-N., Feng, Q., Wang, P., Wang, Y., Qiao, D., Zhou, L., et al. (2023) · Medicine · doi:10.1097/md.0000000000033115 · Cited by 12
Koch, C., Schwing, A. M., Herrmann, E. M., Borner, M., Díaz‐Rubio, E., Dotan, E., Feliú, J., Okita, N. T., Souglakos, J., Arkenau, H. T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23475 · Cited by 10
Self-citationErgün, Y., Açıkgöz, Y., Bal, Ö., Uçar, G., Dirikoç, M., Yıldırım, E. Ç., Akdeniz, N., & Uncu, D. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1693266 · Cited by 10
The Function and Prognostic Significance of Cripto-1 in Colorectal Cancer
Sato, J., Karasawa, H., Suzuki, T., Nakayama, S., Katagiri, M., Maeda, S., Ohnuma, S., Motoi, F., Naitoh, T., & Unno, M. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1741604 · Cited by 9
Yeh, J., Tsai, H., Chen, Y., Li, C., Huang, C., Chang, T., Su, W., Chen, P.-J., Liu, Y., & Wang, J. (2021) · Medicina · doi:10.3390/medicina57121339 · Cited by 10
Woischke, C., Jung, P., Jung, A., Kumbrink, J., Eisenlohr, S., Auernhammer, C. J., Vieth, M. W., Kirchner, T., & Neumann, J. H. L. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.183 · Cited by 11
Self-citationBessudo, A., Haseeb, A., Reeves, J. A., Zhu, X., Wong, L., Giranda, V. L., Suttner, L. H., Liu, F., Chatterjee, M. S., & Sharma, S. K. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.003 · Cited by 14
Lee, S. T., Tebbutt, N. C., Gan, H. K., Liu, Z., Sachinidis, J. I., Pathmaraj, K., & Scott, A. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.606210 · Cited by 8
Kobayashi, S., Bando, H., Taketomi, A., Takamoto, T., Shinozaki, E., Shiozawa, M., Hara, H., Yamazaki, K., Komori, K., Matsuhashi, N., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11311-5 · Cited by 10
Downregulation of miR‑143 modulates KRAS expression in colorectal carcinoma cells
Liu, H., Liu, J., Huo, J., Li, K., Li, K., Guo, H., & Yang, Y. (2019) · Oncology Reports · doi:10.3892/or.2019.7359 · Cited by 8
Laparoscopy and survival in colon cancer: A further step beyond the non-inferiority?
Sorrentino, L., Cosimelli, M., & Sampietro, G. M. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.05.008 · Cited by 8
Sakamoto, K., Beppu, T., Honda, G., Kotake, K., Yamamoto, M., Takahashi, K., Endo, I., Hasegawa, K., Itabashi, M., Hashiguchi, Y., et al. (2024) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.12078 · Cited by 7
Lu, P., Su, X., Leong, S., Xiu, X., Song, P., Peng, J., & Si, Y. (2025) · Biosensors · doi:10.3390/bios15050308 · Cited by 8
Kavgacı, G., Akiva, İ., Ozon, Y. H., Berkil, H., Karadayi, H., Dizdar, O., & Yalçın, Ş. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70042 · Cited by 11
Wu, Y., Xu, Y., Chen, Y., Xu, W., Yao, M., & Ding, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-10592-z · Cited by 10
Strelez, C., Battaglin, F., Perez, R. G., Yang, Y., Cherry, C., Millstein, J., Yoon, A. Y., Chlystek, J. S., Canfield, E. J., Haliday, B., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03546-2 · Cited by 10
Morken, S., Langer, S. W., Hjortland, G. O., Sundlöv, A., Hofsli, E., Ladekarl, M. B., Tabaksblat, E. M., Vestermark, L. W., Svensson, J. B., Knigge, U., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70367 · Cited by 7
Sirkiä, O., Karjalainen, H., Elomaa, H., Väyrynen, S. A., Tuomisto, A., Sirniö, P., Äijälä, V. K., Tapiainen, V. V., Kastinen, M., Wirta, E., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4083 · Cited by 7
Mutation status and surgical selection
Margonis, G. A., Kreis, M. E., Wolfgang, C. L., & Weiss, M. J. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25413 · Cited by 7
Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
Rosati, G., Aprile, G., Basile, D., & Avallone, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602596 · Cited by 7
Coupez, D., Hulo, P., Touchefeu, Y., Denis, M. G., & Bennouna, J. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1967318 · Cited by 9
Lee, T. H., Kang, H., Chie, E. K., Kim, H., Wu, H. G., Lee, J. H., & Kim, K. S. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.03.008 · Cited by 6
Formica, V., Morelli, C., Conca, V., Calegari, M. A., Lucchetti, J., Dell’Aquila, E., Schirripa, M., Messina, M., Salvatore, L., Prinzi, F. L., et al. (2023) · Cancers · doi:10.3390/cancers15113064 · Cited by 6
Warnecke, B., & Nagasaka, M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s466217 · Cited by 7
Reduced RANBP9 expression is associated with poor prognosis in colorectal cancer patients
Wu, G., Li, J., & Qin, C. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.10.24 · Cited by 6
Alfonso, P. G., González, G. G., Gallego, I., Peligros, M. I., Ortega, L., Pérez-Solero, G. T., Sandoval, C., Martín, Á., Codesido, M. B., Ferrándiz, A. C., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02402-x · Cited by 6
Ras Isoforms from Lab Benches to Lives—What Are We Missing and How Far Are We?
Nair, A., Kubatzky, K. F., & Saha, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126508 · Cited by 8
Rasool, M., Carracedo, Á., Sibiany, A., Al-Sayes, F., Karim, S., Haque, A., Pushparaj, P. N., Asif, M., & Achakzai, N. M. (2021) · Bioengineered · doi:10.1080/21655979.2021.1960715 · Cited by 7
Uutela, A., Nordin, A. J., Österlund, E., Halonen, P., Kallio, R., Soveri, L., Salminen, T., Ålgars, A., Ristimaki, A. P., Ovissi, A., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac424 · Cited by 7
Ugai, S., Yao, Q., Takashima, Y., Zhong, Y., Matsuda, K., Kawamura, H., Imamura, Y., Okadome, K., Mima, K., Arima, K., et al. (2024) · Cancer Science · doi:10.1111/cas.16262 · Cited by 9
Homeopathy, Fundamentalism, and the Memory of Water
Milgrom, L. R. (2007) · Current Oncology · doi:10.3747/co.2007.161 · Cited by 8
Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions
Zhu, G., Pei, L., Ye, D., Tang, Q., Xu, H., & Bi, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189382 · Cited by 7
Metadata
- Authors
- Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., Giessen-Jung, C., Stahler, A., Schmoll, H. J., Jung, A., Kirchner, T., Tannapfel, A., & Reinacher-Schick, A.
- Affiliations
- German Cancer Research Center (DE)
- Ludwig-Maximilians-Universität München (DE)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Kliniken Maria Hilf (DE)
- LMU Klinikum (DE)
- University Hospital in Halle (DE)
- Ruhr University Bochum (DE)
- Corresponding author
- Modest, D.P.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 27
- Issue
- 9
- Pages
- 1746-1753
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4999563
- OpenAlex
- W2465450966
- Semantic Scholar
- c6c03496c35c248a5905726558f97863fff59b9b
- Cited by
- 351
- References
- 31
- Citations by year
- 2026: 25 · 2025: 48 · 2024: 63 · 2023: 50 · 2022: 33 · 2021: 39 · 2020: 40 · 2019: 20 · 2018: 15 · 2017: 15 · 2016: 2
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 1160 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, KRAS mutation, NRAS mutation, BRAF mutation, KRAS G12C, KRAS G13D, first-line therapy, progression-free survival, overall survival, predictive biomarkers, prognostic factors
- MeSH terms
- Female, Humans, Male, Membrane Proteins, Mutation, Neoplasm Metastasis, Colorectal Neoplasms, Randomized Controlled Trials as Topic, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease-Free Survival, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.